<SUBMISSION>
<ACCESSION-NUMBER>0000950148-02-002799
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20021126
<ITEMS>5
<ITEMS>7
<FILING-DATE>20021127
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>02842857
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v86258e8vk.htm
<DESCRIPTION>FORM 8-K DATED NOVEMBER 26, 2002
<TEXT>
<HTML>
<HEAD>
<TITLE>ADVANCED BIOTHERAPY, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="center"><FONT size="4"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR></B></FONT>
<FONT size="2"><B>Washington, DC 20549</B></FONT>

<P align="center"><FONT size="4"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="2"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT>

<P align="center"><FONT size="2">Date of Report (Date of earliest reported) November&nbsp;26, 2002</FONT>

<P align="center"><FONT size="4"><B>Advanced Biotherapy, Inc.</B></FONT>

<HR width="36%" align="center" size="1" noshade>

<DIV align="center"><FONT size="2">(Exact name of registrant as specified in its chapter)</FONT></DIV>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="30%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="30%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="30%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">
Delaware</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
0-26323
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">95-0402415</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
<HR size="1" noshade>
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
(Commission<BR>
File Number)
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">(IRS Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="45%">&nbsp;</TD>
        <TD width="10%">&nbsp;</TD>
        <TD width="45%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510<BR>
Woodland Hills, California</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
&nbsp;<BR>
91367</FONT></TD>
</TR>
<TR>
        <TD align="center" valign="top"><HR size="1" noshade></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
<HR size="1" noshade></FONT></TD>
</TR>
<TR valign="bottom">
        <TD align="center" valign="top"><FONT size="2">(Address of principal executive offices)</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="center" valign="top"><FONT size="2">
(Zip Code)</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">Registrant&#146;s telephone number, including area code (818)&nbsp;883-6716</FONT>

<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="v86258exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>


<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on November&nbsp;26, 2002, which
reported that Advanced Biotherapy, Inc. has a patent application pending for
the exclusive use of any form of antibody to gamma interferon (IFN-g) for the
treatment of Pemphigus Vulgaris.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
   <TD width="1%" align="right" nowrap><FONT size="2">(c)</FONT></TD>
   <TD width="1%" nowrap><FONT size="2">&nbsp;&nbsp;</FONT></TD>
   <TD width="98%"><FONT size="2">Exhibits.</FONT></TD>
</TR>
</TABLE>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="8%">&nbsp;</TD>
        <TD width="5%">&nbsp;</TD>
        <TD width="87%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Designation</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="left"><FONT size="1">Description of Exhibit</FONT></TD>
</TR>

<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="left"><HR size="1" noshade></TD>
</TR>

<TR valign="bottom">
        <TD valign="top" align="center"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">99.1</FONT></DIV></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
Press Release, dated November&nbsp;26, 2002</FONT></DIV></TD>
</TR>
</TABLE>
<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<P align="center"><FONT size="2">Signatures</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
</FONT>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
        <TD width="45%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="3%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="50%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top" colspan="3"><FONT size="2">ADVANCED BIOTHERAPY, INC.<br>
(Registrant)</FONT></TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
        <TD valign="top"><FONT size="2">Date: November&nbsp;26, 2002</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">
By:
</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">/s/ Edmond Buccellato</FONT></TD>
</TR>
<TR>
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><FONT size="2">Edmond Buccellato, President and CEO</FONT></TD>
</TR>
</TABLE>
<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>
<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="60%">
<TR valign="bottom">
        <TD width="10%">&nbsp;</TD>
        <TD width="20%">&nbsp;</TD>
        <TD width="70%">&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><FONT size="1">Exhibit</FONT></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><FONT size="1">Description</FONT></TD>
</TR>
<TR valign="bottom">
        <TD nowrap align="center"><HR size="1" noshade></TD>
        <TD><FONT size="1">&nbsp;</FONT></TD>
        <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
        <TD valign="top" align="center"><FONT size="2">99.1</FONT></TD>
        <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD align="left" valign="top"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">
Text of Press Release, dated November&nbsp;26, 2002</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">&nbsp;
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v86258exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>ADVANCED BIOTHERAPY, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="right"><FONT size="2">EXHIBIT 99.1</FONT>

<P align="left"><FONT size="2"><B>Advanced Biotherapy, Inc. Discloses Results of Pilot Study and Patent Pending
for Exclusive Use of Antibodies to Gamma Interferon for the Treatment of
Pemphigus Vulgaris</B></FONT>

<P><FONT size="2">WOODLAND HILLS, Calif.&#151; (BUSINESS WIRE)&#151; Nov. 26, 2002&#151; Advanced Biotherapy,
Inc. (OTCBB:ADVB) announced today that as part of the Company&#146;s ongoing program
of expanding its patent estate, a patent application is pending for the
exclusive use of any form of antibody to gamma interferon (IFN-g) for the
treatment of Pemphigus Vulgaris. As previously reported, the United States
Patent and Trademark Office (USPTO)&nbsp;issued to the Company U.S. Patent No.
5,888,511 &#147;Treatment of Autoimmune Diseases, including AIDS,&#148; and U.S. Patent
No.&nbsp;6,333,032 for the exclusive use of IFN-g antibodies &#151; including humanized
and fully human, as well as other antibody types &#151; to treat Multiple
Sclerosis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic
Arthritis (a form of psoriasis) and Ankylosing Spondylitis. The company also
has patent applications pending for the exclusive use of any form of antibody
to IFN-g to treat various other autoimmune diseases.
</FONT>
<P><FONT size="2">Commenting on this announcement, Mr.&nbsp;Edmond Buccellato, President and Chief
Executive Officer, stated that &#147;Pemphigus Vulgaris (PV)&nbsp;is an autoimmune
disease causing blistering on the skin and mucous membranes. Those afflicted
suffer from burn-like lesions on their bodies. PV is characterized by sores and
blisters that almost always start in the mouth. Because the skin is an organ,
PV is called a one-organ disease. The blisters can penetrate down to a person&#146;s
vocal cords. The sores may never heal, or may not heal for extended periods of
time. Some patients can coexist with the disease for years, while in its worst
case, those affected can die a slow and complicated death. At the present time,
there is no cure, but treatments are available which lessen the effects of the
disease. These treatments center on the use of steroids such as prednisone and
other corticosteroid medications.&#148;
</FONT>
<P><FONT size="2">He further commented, &#147;In a pilot study at the Division of Dermatology and
Venereal Disease, Moscow State Medical University, Russia, that stabilization
of the pathological process of PV, after 5&nbsp;days of treatment with antibodies to
IFN-g, showed efficacy, was well tolerated, and in management&#146;s opinion
provides supportive proof in principle in humans. While the company has a
well-defined strategy to pursue clinical trials for indications that have
substantially larger markets, we are allocating certain resources to pursue
indications that have smaller yet lucrative commercialization potential. This
is simply another example of the potentially broad application of our
therapeutic approach to treat various autoimmune diseases.&#148;
</FONT>
<P><FONT size="2">According to the International Pemphigus Foundation, it is estimated that
between 1 and 5 people per hundred thousand are affected across racial and
cultural lines. However, there are certain groups of people (such as eastern
European Jews and people of Mediterranean descent) who have a higher incidence
of the disease. Men and women are equally affected. Although the onset usually
occurs in middle-aged and older adults, the disease also occurs in young adults
and children.
</FONT>
<P><FONT size="2">Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties
that could cause actual results to differ materially from the anticipated
results or other expectations expressed in our forward-looking statements. The
risks and uncertainties which may affect the development, operations and
results of our business include, but are not limited to the following: risks
associated with clinical trials, the uncertainties of research and product
development programs, the uncertainties of the regulatory approval process, the
risks of competitive products, the risks of our current capital resources, the
uncertainties as to the availability of future capital and our future capital
requirements, and the risks associated with the extent and breadth of the
Company&#146;s patent portfolio. The foregoing discussion of the effect of the
patents issued and pending involves risks and uncertainties, including but not
limited to the risks that third parties may be successful in challenging such
patents; or that granted claims may be held invalid or interpreted differently
by a court of law; or that new technologies will be developed that are superior
in treating the diseases targeted by Advanced Biotherapy, Inc. Readers are
cautioned not to place reliance on these forward-looking statements, which
speak only as of the date the statements were made. See the Company&#146;s public
filings with the Securities and Exchange Commission for further information
about risks and uncertainties that may affect the Company and the
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P><FONT size="2">results or expectations expressed in our forward-looking statements, including
the section captioned &#147;Factors That May Affect The Company&#148; contained in the
Company&#146;s Annual Report on Form&nbsp;10-KSB for the fiscal year ended December&nbsp;31,
2001.
</FONT>
<P><FONT size="2">CONTACT:
</FONT>
<P><FONT size="2">Advanced Biotherapy, Inc.
</FONT>
<P><FONT size="2">Edmond Buccellato, 818/883-6716
</FONT>
<P><FONT size="2">www.advancedbiotherapy.com
</FONT>
<P><FONT size="2">SOURCE: Advanced Biotherapy, Inc.
</FONT>
<P><FONT size="2">Today&#146;s News On The Net &#151; Business Wire&#146;s full file on the Internet with Hyperlinks to your home page.<BR>
URL: http://www.businesswire.com
</FONT>
<P><FONT size="2">11/26/2002 10:00 EASTERN
</FONT>

<P align="center"><FONT size="2">&nbsp;</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
